Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study

Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers.
Data showed statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers.
The treatment showed a significant positive impact at 50 mcg/day dose (compared to other dose and placebo groups) on T-cell subsets and inflammatory biomarkers.
It was well-tolerated at all doses, and there were no apparent symptoms of severe toxicity.
Statistically significant stimulation in the production of anti-inflammatory cytokine IL-10 along with suppressed production of pro-inflammatory cytokine IFN-γ suggested a positive trend for immunomodulation and anti-inflammatory effect.
Yesterday, the company dosed the first patient with secondary progressive multiple sclerosis with nasally administered foralumab.
Price Action: TLSA shares closed at $2.4 on Tuesday.